BioCentury

8:00 AM GMT, Feb 7, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Networked in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking.

In January, Ligand granted Chiva Pharmaceuticals Inc. rights to develop and commercialize HBV candidate pradefovir and liver cancer candidate MB01733 in China. Pradefovir has completed Phase II studies while MB01733 has completed a Phase

Read the full 613 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.